Microbot Medical Closes $13 Million Registered Direct Offering: A Boost for Endovascular Robotics

Microbot Medical Inc. (Nasdaq: MBOT), a pioneering medical device company specializing in robotic endoluminal surgery devices, has recently closed a $13 million registered direct offering. This funding round, priced at-the-market under Nasdaq rules, is a testament to the company's potential and the growing interest in its innovative technology. The funds raised will be instrumental in supporting Microbot Medical's ongoing research and development efforts, as well as its expansion into new markets.



The company's flagship product, LIBERTY, is an endovascular robotic surgical system that allows physicians to conduct catheter-based procedures from outside the catheterization laboratory. This innovative technology enables physicians to avoid radiation exposure, physical strain, and the risk of cross-contamination, making it an attractive option for use in cardiovascular, peripheral, and neurovascular spaces. The successful completion of the pivotal human clinical trial for LIBERTY, along with the company's strategic collaboration agreement with Stryker Corporation for technology co-development, further solidifies Microbot Medical's position in the endovascular robotics market.

Microbot Medical's focus on preparing for the commercial launch of LIBERTY in 2025 aligns with its financial goals and market positioning. The company's recent funding rounds, including the $8.6 million registered direct offering in January 2025 and the $13 million offering in February 2025, have strengthened its financial position and provided the necessary capital to support its growth. Additionally, the company's revenue is expected to grow to $6.12 million in 2025, indicating a positive financial outlook that supports its strategic growth plan.

In conclusion, Microbot Medical's recent $13 million registered direct offering is a significant development that underscores the company's potential and the growing interest in its innovative endovascular robotics technology. With a strong financial position and a clear strategic focus on the commercial launch of LIBERTY in 2025, Microbot Medical is well-positioned to capture market share in the endovascular robotics space and solidify its position as a leader in the field.